<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00391755</url>
  </required_header>
  <id_info>
    <org_study_id>06-013R</org_study_id>
    <nct_id>NCT00391755</nct_id>
  </id_info>
  <brief_title>A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches</brief_title>
  <official_title>A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charlottesville Neuroscience</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda Pharmaceuticals North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charlottesville Neuroscience</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effect of Rozerem, a high affinity MT1 and MT2, low affinity 5-HT2B receptor&#xD;
      agonist used for insomnia, as a migraine prophylactic agent.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a recent, large study of migraineurs, over half reported difficulties with sleep&#xD;
      initiation or maintenance. Those who had shorter average sleep times reported more severe&#xD;
      headaches. Poor sleep has been associated with increased frequency and severity of migraines.&#xD;
      The improvement of migraine frequency with improved sleep hygiene has been documented.&#xD;
&#xD;
      PET imaging has shown increased regional cerebral blood flow to neural structures involved in&#xD;
      the sleep wake cycle during migraine headaches. Polysomnography has shown specific headache&#xD;
      types to occur in specific sleep stages.&#xD;
&#xD;
      Melatonin has been effective primarily in headache due to delayed sleep phase syndrome.&#xD;
      Recent studies support the efficacy of melatonin in treating migraine. The purpose of this&#xD;
      study is to examine the efficacy of Rozerem as a prophylactic migraine medication. If&#xD;
      effective, the benefits of the drug as a prophylactic agent for migraine include the&#xD;
      tolerability of the drug and the possible secondary benefit of improvement in sleep.&#xD;
&#xD;
      Hypothesis: Rozerem will decrease migraine frequency due to the improvement in sleep and&#xD;
      possibly due to the shared neurophysiology of sleep and migraine affected by melatonin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Failure to recruit necessary number of patients.&#xD;
  </why_stopped>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Statistically significant reduction in migraine headaches in the Rozerem treated group.</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in sleep satisfaction in the Rozerem treated group.</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Migraine Headache</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ramelteon 8 mg po qhs with sleep and migraine journal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo po qhs with sleep and migraine journal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ramelteon</intervention_name>
    <description>ramelteon 8mg po qhs with sleep and headache diary&#xD;
placebo 1 po qhs with sleep and headache diary</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Rozerem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-65&#xD;
&#xD;
          -  3-8 Migraine headaches/month&#xD;
&#xD;
          -  Able to understand and comply with the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently on migraine prophylaxis&#xD;
&#xD;
          -  Currently on sleep medication &gt; 4days/month&#xD;
&#xD;
          -  Currently on Fluvoxamine&#xD;
&#xD;
          -  Untreated psychiatric or sleep disorders&#xD;
&#xD;
          -  MRI abnormalities other than those attributable to migraine headaches&#xD;
&#xD;
          -  Abnormalities on neurological exam other than known neurological disorders&#xD;
             unassociated with migraine or sleep&#xD;
&#xD;
          -  Known disorders of prolactin&#xD;
&#xD;
          -  Bipolar disorder&#xD;
&#xD;
          -  Hepatic disease&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia J Shipley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charlottesville Neuroscience</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Patricia Shipley, MD</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sahota PK, Dexter JD. Sleep and headache syndromes: a clinical review. Headache. 1990 Jan;30(2):80-4. Review.</citation>
    <PMID>2406223</PMID>
  </reference>
  <reference>
    <citation>Kelman L, Rains JC. Headache and sleep: examination of sleep patterns and complaints in a large clinical sample of migraineurs. Headache. 2005 Jul-Aug;45(7):904-10.</citation>
    <PMID>15985108</PMID>
  </reference>
  <reference>
    <citation>Boardman HF, Thomas E, Millson DS, Croft PR. Psychological, sleep, lifestyle, and comorbid associations with headache. Headache. 2005 Jun;45(6):657-69.</citation>
    <PMID>15953298</PMID>
  </reference>
  <reference>
    <citation>Bruni O, Galli F, Guidetti V. Sleep hygiene and migraine in children and adolescents. Cephalalgia. 1999 Dec;19 Suppl 25:57-9.</citation>
    <PMID>10668125</PMID>
  </reference>
  <reference>
    <citation>Bahra A, Matharu MS, Buchel C, Frackowiak RS, Goadsby PJ. Brainstem activation specific to migraine headache. Lancet. 2001 Mar 31;357(9261):1016-7.</citation>
    <PMID>11293599</PMID>
  </reference>
  <reference>
    <citation>Peres MF. Melatonin, the pineal gland and their implications for headache disorders. Cephalalgia. 2005 Jun;25(6):403-11. Review.</citation>
    <PMID>15910564</PMID>
  </reference>
  <reference>
    <citation>Peres MF, Zukerman E, da Cunha Tanuri F, Moreira FR, Cipolla-Neto J. Melatonin, 3 mg, is effective for migraine prevention. Neurology. 2004 Aug 24;63(4):757.</citation>
    <PMID>15326268</PMID>
  </reference>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>October 22, 2006</study_first_submitted>
  <study_first_submitted_qc>October 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2006</study_first_posted>
  <last_update_submitted>February 8, 2012</last_update_submitted>
  <last_update_submitted_qc>February 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charlottesville Neuroscience</investigator_affiliation>
    <investigator_full_name>Patricia Shipley, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Migraine Headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

